secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2022-06-06T23:59:59+00:00
Accession:  0001104659-22-068301
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA Phase 1 HB-200 shows 80% disease control with alternating 2-vector; Phase 2 initiated
--------------------------------------------------------------------------------

- Alternating 2-vector HB-202/HB-201 achieved 80% disease control rate vs historical 35-40% for pembrolizumab.
- 56% of alternating 2-vector patients had target lesion shrinkage vs 38% for single-vector HB-201.
- 32% on alternating 2-vector had tumor-specific T cells >5% of circulating pool vs 7% on HB-201.
- HB-200 well tolerated; only 8.8% grade ≥3 treatment-related side effects, mostly flu-like symptoms.
- Phase 2 plans include combos with pembrolizumab; initial results expected H2 2022, randomized trial H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465922068301/0001104659-22-068301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465922068301/tm2217741d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-068301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer